Alzheimer's pipeline hits 158 therapies

Alzheimer’s drug development just got a lot bigger — and a lot messier. The new 2026 pipeline review counts 158 therapies being tested across 192 clinical trials, up from 138 drugs and 182 trials in the 2025 review. That matters because Alzheimer’s has spent decades as a graveyard for drug programs. What changed is not just the number of shots on goal, but the kinds of shots researchers are taking. ### What is this number actually counting? It is not 158 approved medicines or even 158 late-stage contenders. It is 158 distinct drugs currently in human testing for Alzheimer’s disease, pulled from trials registered on ClinicalTrials.gov and grouped across Phase 1, Phase 2, and Phase 3. The same review puts the total at 192 active trials, which tells you one drug can appear in more than one study or stage. ### Why is 158 a big deal? Because the pipeline was meaningfully smaller a year ago. The 2025 review counted 138 drugs in 182 trials. The Alzheimer’s Association says the new tally is also up about 35% versus a decade ago, with trials up roughly 40% over that span. So this is not a one-quarter blip — it looks like a sustained expansion in how much money and scientific effort is flowing into the field. ### Why are repurposed drugs such a big chunk? Repurposing means taking a drug already approved, or at least already developed, for another disease and testing whether it can help in Alzheimer’s. In the 2026 pipeline, 56 agents fit that bucket — 35% of all drugs in trials. The appeal is obvious: safety, dosing, and manufacturing are often better understood than the brain, which is the hard part. ### Is this still mostly about amyloid? No — and that is one of the most important changes. The field still includes amyloid drugs, and those remain central because that is where the first disease-modifying approvals came from. But the 2026 review and outside summaries both point to a broader mix now, with developers pushing into tau, inflammation, immune pathway-targeting drugs are now about 20% of the pipeline, down from roughly one-third a decade ago. ### Where is the real weight in the pipeline? Late-stage trials. The review says active studies will need 54,728 participants in total, and 38,417 of those slots sit in Phase 3. Industry sponsors 59% of all Alzheimer’s trials and 72% of Phase 3 trials. Basically, the expensive part of the machine is being driven largely by biopharma, which is a sign of confidence but also a reminder that commercial filters shape what gets tested. ### Does a bigger pipeline mean better odds? Not automatically. A bigger pipeline means more scientific diversity and more ways to win, but it also means more competition for patients, trial sites, biomarkers, and clinician time. Alzheimer’s trials are slow, expensive, and picky about enrollment. Repurposed drugs help on cost, but they do not solve the basic biology, which is why a growing pipeline can be both encouraging and chaotic. ### What should readers take from this? The simplest read is that Alzheimer’s research is no longer stuck in a single-lane amyloid bet. The field now has more programs, more mechanisms, and more willingness to test old drugs in new ways. That does not guarantee a wave of wins. But it does mean the pipeline is starting to look less like a monoculture and more like a real portfolio — which is usually what progress looks like before the breakthroughs become obvious.